FLUOXETINE

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H18F3NO
Molecular Weight	309.3261
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C2=CC=CC=C2

InChI

InChIKey=RTHCYVBBDHJXIQ-UHFFFAOYSA-N

InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3

HIDE SMILES / InChI

Molecular Formula	C17H18F3NO
Molecular Weight	309.3261
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf | https://www.drugs.com/fluoxetine.html

Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs). Fluoxetine is a racemic mixture of the R- and S- enantiomers and are of equivalent pharmacologic activity. Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Fluoxetine is marketed under the trade names Prozac and Sarafem among others. It is also marketed for the treatment of premenstrual dysphoric disorder (Sarafem®, fluoxetine hydrochloride). PROZAC is a selective serotonin reuptake inhibitor indicated for: • Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years • Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adult and pediatric patients aged 7 to 17 years • Acute and maintenance treatment of Bulimia Nervosa in adult patients • Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients. Studies at clinically relevant doses in man have demonstrated that fluoxetine blocks the uptake of serotonin into human platelets. Studies in animals also suggest that fluoxetine is a much more potent uptake inhibitor of serotonin than of norepinephrine. Antagonism of muscarinic, histaminergic, and α1-adrenergic receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects of classical tricyclic antidepressant (TCA) drugs. Fluoxetine binds to these and other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin transporter 177 Target ID: CHEMBL228 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/9537821 \| https://www.ncbi.nlm.nih.gov/pubmed/19329313 \| https://www.ncbi.nlm.nih.gov/pubmed/17910821	Inhibitor 8228		10.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Major depressive disorder 172 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf	Primary	Approved 8360	PROZAC Approved Use Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years (1.1) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adult and pediatric patients aged 7 to 17 years (1.2) Acute and maintenance treatment of Bulimia Nervosa in adult patients (1.3) Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients (1.4) Fluoxetine and olanzapine in combination for: Acute treatment of Depressive Episodes Associated with Bipolar I Disorder in adults (1.5) 1.1 Major Depressive Disorder Fluoxetine hydrochloride is indicated for the acute and maintenance treatment of Major Depressive Disorder in adult patients and in pediatric patients aged 8 to18 years [see CLINICAL STUDIES (14.1) Launch Date 5.6773437E11
Obsessive-compulsive disorder 28 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf	Primary	Approved 8360	PROZAC Approved Use Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years (1.1) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adult and pediatric patients aged 7 to 17 years (1.2) Acute and maintenance treatment of Bulimia Nervosa in adult patients (1.3) Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients (1.4) Fluoxetine and olanzapine in combination for: Acute treatment of Depressive Episodes Associated with Bipolar I Disorder in adults (1.5) 1.1 Major Depressive Disorder Fluoxetine hydrochloride is indicated for the acute and maintenance treatment of Major Depressive Disorder in adult patients and in pediatric patients aged 8 to18 years [see CLINICAL STUDIES (14.1) Launch Date 5.6773437E11
Bulimia nervosa 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf	Primary	Approved 8360	PROZAC Approved Use Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years (1.1) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adult and pediatric patients aged 7 to 17 years (1.2) Acute and maintenance treatment of Bulimia Nervosa in adult patients (1.3) Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients (1.4) Fluoxetine and olanzapine in combination for: Acute treatment of Depressive Episodes Associated with Bipolar I Disorder in adults (1.5) 1.1 Major Depressive Disorder Fluoxetine hydrochloride is indicated for the acute and maintenance treatment of Major Depressive Disorder in adult patients and in pediatric patients aged 8 to18 years [see CLINICAL STUDIES (14.1) Launch Date 5.6773437E11
Panic disorder 22 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf	Primary	Approved 8360	PROZAC Approved Use Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years (1.1) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adult and pediatric patients aged 7 to 17 years (1.2) Acute and maintenance treatment of Bulimia Nervosa in adult patients (1.3) Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients (1.4) Fluoxetine and olanzapine in combination for: Acute treatment of Depressive Episodes Associated with Bipolar I Disorder in adults (1.5) 1.1 Major Depressive Disorder Fluoxetine hydrochloride is indicated for the acute and maintenance treatment of Major Depressive Disorder in adult patients and in pediatric patients aged 8 to18 years [see CLINICAL STUDIES (14.1) Launch Date 5.6773437E11

C_max

Value	Dose	Co-administered	Analyte	Population
22.56 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15968712	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
13576.38 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16229112	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
1101.46 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15968712	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
788626.72 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16229112	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
46.39 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15968712	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
49.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16229112	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
5.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf			FLUOXETINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1579 substrate 1709	inhibitor 1752 substrate 1010	inhibitor 1837 substrate 1193	inhibitor 1599

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
Cav3.1 7 Cav3.2 12 Cav3.3 7 P-gp 1437 CYP2C19 1463 OCT1 506 OCT2 638	P-gp 1527 CYP1A2 1032 CYP2B6 660 CYP2C19 985 CYP3A5 391	BCRP 75

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1626	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/12649369/ \| https://pubmed.ncbi.nlm.nih.gov/21718296/ \| https://pubmed.ncbi.nlm.nih.gov/17962372/	moderate [IC50 31 uM]
CYP3A4 1909	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/11876575/	moderate	norfluoxetine 2
P-gp 1626	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/12649369/	moderate	norfluoxetine 2
CYP3A4 1909	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/12172343/	moderate		yes (co-administration study) Comment: addition of fluoxetine 20 mg/day to pre-existing risperidone therapy produced a mean 4- fold increase in plasma risperidone concentration, with some patients exhibiting an increase as large as 10-fold Sources: https://pubmed.ncbi.nlm.nih.gov/12172343/
BCRP 765	inducer 1542 Sources: https://pubmed.ncbi.nlm.nih.gov/31037729/	no
CYP2D6 1875	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/12172343/ \| https://pubmed.ncbi.nlm.nih.gov/27188854/ \| https://pubmed.ncbi.nlm.nih.gov/11876575/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf	strong [IC50 1.05 uM]		yes (co-administration study) Comment: Coadministration of fluoxetine with other drugs that are metabolized by CYP2D6, including certain antidepressants (e.g., TCAs), antipsychotics (e.g., phenothiazines and most atypicals), and antiarrhythmics (e.g., propafenone, flecainide, and others) should be approached with caution Sources: https://pubmed.ncbi.nlm.nih.gov/12172343/ \| https://pubmed.ncbi.nlm.nih.gov/27188854/ \| https://pubmed.ncbi.nlm.nih.gov/11876575/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf
Cav3.1 7	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/16510561/	yes [IC50 14 uM]
Cav3.2 12	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/16510561/	yes [IC50 16 uM]
OCT2 639	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/30361780/	yes [IC50 3.32 uM]
Cav3.3 7	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/16510561/	yes [IC50 30 uM]
Cav3.3 7	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/16510561/	yes [IC50 5 uM]	norfluoxetine 2
OCT1 523	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/24688079/ \| https://pubmed.ncbi.nlm.nih.gov/30361780/	yes [IC50 6.2 uM]
CYP2C9 1803	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/9384467/	yes
CYP2C19 1537	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/11270912/	yes		yes (co-administration study) Comment: Fluoxetine dosing inhibited CYP2C19 activity in both age groups, increasing the (S)- to (R)-mephenytoin ratio 3- to 4-fold Sources: https://pubmed.ncbi.nlm.nih.gov/11270912/

Drug as victim

Target	Modality	Activity
P-gp 1527	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/21718296/ \| https://pubmed.ncbi.nlm.nih.gov/17962372/	minor
CYP2C9 1010	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/\| https://pubmed.ncbi.nlm.nih.gov/24464553/	yes [Ki 19 uM]
CYP1A2 1032	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/	yes
CYP2B6 660	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/	yes
CYP2C19 985	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/	yes
CYP2D6 1193	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/ \| https://pubmed.ncbi.nlm.nih.gov/16472103/ \| https://pubmed.ncbi.nlm.nih.gov/24464553/	yes
CYP3A4 1709	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/	yes
CYP3A5 391	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1632	inhibitor 1613 Sources: https://pubmed.ncbi.nlm.nih.gov/16967046/ \| https://pubmed.ncbi.nlm.nih.gov/11805215/
hERG 1632	inhibitor 1613 Sources: https://pubmed.ncbi.nlm.nih.gov/16967046/		norfluoxetine 2

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B3-034390	http://www.3bsc.com/index/pro_info.php?id=56297
AA Blocks	AA00I9Q5	http://www.aablocks.com/goods/Goods/detail?id=AA00I9Q5
AHH Chemical co.,ltd	MT-51855	http://www.ahhchemical.com/product/MT-51855.html
Aaron Chemicals	AR00IAHX	http://www.aaronchem.com/54910-89-3
Acadechem	ACDC-070879	http://acadechemical.com/product/11474
Achemo Scientific Limited	AC-14816	http://www.achemo.com/product_view.asp?ID=4706
Achemtek	0104-002971	http://www.achemtek.com/54910-89-3
Alfa Chemistry	54910-89-3	https://www.alfa-chemistry.com/fluoxetine-cas-54910-89-3-item-292572.htm
Alinda	ALBB-025606	http://alinda.ru/finechem_en_.html?i=ALBB-025606
ApexBio Technology	A2436	http://www.apexbt.com/fluoxetine-hcl.html
AvaChem Scientific	2877B	http://www.avachem.com/productSearch.asp?2877B
BLD Pharm	BD130609	http://www.bldpharm.com/products/54910-89-3.html
BOC Sciences	1173147-79-9	https://www.bocsci.com/fluoxetine-d5-solution-cas-1173147-79-9-item-185463.html
BioChemPartner	BCP28440	http://www.biochempartner.com/54910-89-3-BCP28440
Chem Scene	CS-2861	http://www.chemscene.com/54910-89-3.html
ChemMol	30103987	http://www.chemmol.com/chemmol/30103987.html
ChemMol	49402399	http://www.chemmol.com/chemmol/49402399.html
Chemenu	CM118045	http://www.chemenu.com/products/CM118045
Chemspace	CSSB00000726877	https://chem-space.com/CSSB00000726877
Clearsynth	CS-O-01527	http://www.clearsynth.com/en/CSO01527.html
Debye Scientific	DB-015148	http://www.debyesci.com/cas_54910-89-3.html
Finetech	FT-0626489	http://www.finetechnology-ind.com/prod/detail/pub/54910-89-3.html
Glentham Life Sciences	GP3875	http://www.glentham.com/products/product/GP3875/
Lab Network	LN00287054	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00287054
MedChem Express	HY-B0102	https://www.medchemexpress.com/fluoxetine.html
MuseChem	I004030	https://www.musechem.com/product/I004030.html
Smolecule	S590536	https://www.smolecule.com/products/s590536
THE BioTek	bt-305245	https://www.thebiotek.com/product/others/bt-305245
Yuhao Chemical	LT4939	http://www.chemyuhao.com/54910-89-3.html
abcr GmbH	AB377357	http://www.abcr.com/shop/en/AB377357
iChemical	EBD34153	http://www.ichemical.com/products/54910-89-3.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
Urinary retention with reboxetine-fluoxetine combination in a young man.	2000 Dec	11190365
Evidence of early onset of antidepressant effect in randomized controlled trials.	2001	11229783
The effects of antidepressants on sexual functioning in depressed patients: a review.	2001	11229450
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.	2001	11229449
Dopaminergic activity in transgenic mice underexpressing glucocorticoid receptors: effect of antidepressants.	2001	11226678
Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness.	2001	11217873
Effects of selective serotonin reuptake inhibitors on sexual function.	2001 Apr	11270925
Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio.	2001 Apr	11270917
Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin.	2001 Apr	11270913
Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers.	2001 Apr	11270912
Serotonergic manipulations both potentiate and reduce brain stimulation reward in rats: involvement of serotonin-1A receptors.	2001 Apr	11259559
Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors.	2001 Apr	11255075
Idazoxan and 8-OH-DPAT modify the behavioral effects induced by either NA, or 5-HT, or dual NA/5-HT reuptake inhibition in the rat forced swimming test.	2001 Apr	11182533
Social impulsivity inversely associated with CSF 5-HIAA and fluoxetine exposure in vervet monkeys.	2001 Apr	11182532
Effect of chronic and acute administration of fluoxetine and its additive effect with morphine on the behavioural response in the formalin test in rats.	2001 Feb	11273019
Characterization of 5-HT receptors in the parasitic nematode, Ascaris suum.	2001 Feb	11272652
Subjective and discriminative stimulus effects of two de-nicotinized cigarettes with different tar yields.	2001 Feb	11260814
[Effect of fluoxetine on histamine content in the rat conjunctiva].	2001 Feb	11240489
Rapid desensitization of 5-HT(1A) receptors in Fawn-Hooded rats after chronic fluoxetine treatment.	2001 Feb	11226808
Severe symptomatic hyponatremia during citalopram therapy.	2001 Feb	11217819
Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers.	2001 Feb	11213850
Reversible galactorrhea and prolactin elevation related to fluoxetine use.	2001 Feb	11213313
Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers.	2001 Feb	11210405
Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo.	2001 Feb	11199947
Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors.	2001 Feb	11199945
The economic consequences of a drug-drug interaction.	2001 Feb	11199940
Dose-dependent seizure activity associated with fluoxetine therapy.	2001 Feb	11181988
Acute hypokalemic paralysis associated with long-term lithium therapy.	2001 Feb	11180215
Psychopharmacologic treatment of adolescent depression.	2001 Feb	11172238
Fluoxetine and side effects in the geriatric population.	2001 Feb 1	11272295
A compulsive collecting behavior following an A-com aneurysmal rupture.	2001 Feb 13	11171910
Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity.	2001 Feb 23	11263672
Fluoxetine (Prozac) as a cause of QT prolongation.	2001 Feb 26	11252125
[Ten questions on the treatment of obesity: from dieting to surgery].	2001 Jan	11234711
Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients.	2001 Jan	11225566
Transient ST segment elevation in right precordial leads induced by psychotropic drugs: relationship to the Brugada syndrome.	2001 Jan	11204086
Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone.	2001 Jan	11202131
Treatment of bipolar depression with twice-weekly fluoxetine: management of antidepressant-induced mania.	2001 Jan	11197585
Fluoxetine-induced Ca2+ signals in Madin-Darby canine kidney cells.	2001 Jan	11191831
Central 5-hydroxytryptamine-2A receptor expression in transgenic mice bearing a glucocorticoid receptor antisense.	2001 Jan	11174015
Fluoxetine in the treatment of Huntington's disease.	2001 Jan 1	11205429
Fluoxetine (Sarafem) for premenstrual dysphoric disorder.	2001 Jan 22	11177220
Plasticity in serotonin uptake in primary neuronal cultures of serotonin transporter knockout mice.	2001 Jan 31	11172895
Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS).	2001 Jan-Feb	11226552
Mutism: elective or selective, and acquired.	2001 Mar	11248456
Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.	2001 Mar	11181904
Addition of a 5-HT receptor agonist to methylphenidate potentiates the reduction of [123I]FP-CIT binding to dopamine transporters in rat frontal cortex and hippocampus.	2001 Mar 1	11169768
Modafinil does not affect serotonin efflux from rat frontal cortex synaptosomes: comparison with known serotonergic drugs.	2001 Mar 16	11251206
Repeated electroconvulsive stimulation, but not antidepressant drugs, induces mossy fibre sprouting in the rat hippocampus.	2001 Mar 2	11222992
Adding group psychotherapy to medication treatment in dysthymia: a randomized prospective pilot study.	2001 Spring	11264333

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Bulimia Immediate-release oral formulations: Recommended dose: 60 mg orally once a day Usual Adult Dose for Depression Immediate-release oral formulations: Initial dose: 20 mg orally once a day, increased after several weeks if insufficient clinical improvement is observed Maintenance dose: 20 to 60 mg orally per day Maximum dose: 80 mg orally per day Delayed release oral capsules: Initial dose: 90 mg orally once a week, commenced 7 days after the last daily dose of immediate-release fluoxetine 20 mg formulations. Usual Adult Dose for Obsessive Compulsive Disorder Immediate-release oral formulations: Initial dose: 20 mg orally once a day, increased after several weeks if insufficient clinical improvement is observed. Maintenance dose: 20 to 60 mg orally per day Maximum dose: 80 mg orally per day Usual Adult Dose for Panic Disorder Immediate-release oral formulations: Initial dose: 10 mg orally once a day, increased after one week to 20 mg orally once a day Maintenance dose: 20 to 60 mg orally per day Maximum dose: 60 mg orally per day

Route of Administration: Oral

In Vitro Use Guide

Caco-2 SERT was also shown to be a high affinity (Kt=0.216 uM) saturable, Na(+) -dependent transporter that was inhibited by fluoxetine (IC(50)=17.6 nM).

Substance Class	Chemical Created by `admin` on `Wed Jul 05 23:05:50 UTC 2023` Edited by `admin` on `Wed Jul 05 23:05:50 UTC 2023`
Record UNII	01K63SUP8D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FLUOXETINE

Official Name

English

fluoxetine [INN]

Common Name

English

(±)-N-METHYL-3-PHENYL-3-((.ALPHA.,ALPHA.,.ALPHA.-TRIFLUORO-P-TOLYL)OXY)PROPYLAMINE

Common Name

English

FLUOXETIN RATIOPHARM

Common Name

English

DL-N-METHYL-3-(P-TRIFLUOROMETHYLPHENOXY)-3-PHENYLPROPYLAMINE

Common Name

English

FLUOXETINE [USAN]

Common Name

English

NSC-283480

Code

English

NSC-758685

Code

English

Fluoxetine [WHO-DD]

Common Name

English

FLUOXETINE [EMA EPAR VETERINARY]

Common Name

English

FLUOXETINE [VANDF]

Common Name

English

N-METHYL-.GAMMA.-(4-(TRIFLUOROMETHYL)PHENOXY)BENZENEPROPANAMINE

Systematic Name

English

FLUOXETINE [MI]

Common Name

English

FLUVAL

Common Name

English

BENZENEPROPANAMINE, N-METHYL-G-(4-(TRIFLUOROMETHYL)PHENOXY)-, (±)-

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

183504